REG - IXICO plc - Issue of Equity

IXICOAnnouncement

22/04/2026 12:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260422:nRSV5247Ba&default-theme=true

RNS Number : 5247B  IXICO plc  22 April 2026

IXICO PLC

("IXICO" or the "Company")

Issue of Equity

IXICO plc (AIM: IXI), a global leader in neuroscience imaging and biomarker
analytics, using its AI-driven platform to help advance drug development in
neurological disorders, announces that further to the 'Placings and
Subscription' announcement dated 31 March 2026, the Company is pleased to
confirm that it has now received Advance Assurance from HM Revenue &
Customs under the Income Tax Act 2007. Consequently, all conditions relating
to the First Placing and Subscription have been satisfied.

Director Shareholdings

The following Directors subscribed for New Ordinary Shares pursuant to the
Fundraising. The number of new Ordinary Shares subscribed for by each Director
and their resulting shareholdings upon Admission are set out below:

 Name              Number of existing Ordinary Shares  Number of Subscription Shares subscribed for ((1))   Number of Ordinary Shares held following Admission
 Mark Warne        72,335                              125,000                                              197,335
 Bram Goorden      526,315                             937,500                                              1,463,815
 Katherine Rogers  52,631                              62,500                                               115,131

 

(1)  The number of Ordinary Shares presented in this table as being held or
subscribed for by Directors refers to the number of Ordinary Shares held or
subscribed for by them either personally or through a nominee.

 

The notifications below, made in accordance with the requirements of the UK
Market Abuse Regulation, provide further details.

Admission and Total Voting Rights

Application has been made for the New Ordinary Shares to be admitted to
trading on AIM. It is expected that First Admission will become effective at
8.00 a.m. on 24 April 2026 and Second Admission will become effective at 8.00
a.m. on 27 April 2026.

Following First Admission and Second Admission, the total number of Ordinary
Shares in the capital of the Company in issue will be 218,047,596 with each
Ordinary Share carrying the right to one vote. There are no shares held in
treasury and therefore, following Fist Admission and Second Admission, the
total number of voting rights in the Company will be 218,047,596.

The above figure may be used by Shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the share capital of the
Company under the FCA's Disclosure, Guidance and Transparency Rules.

Capitalised terms used in this announcement have the meaning given to them in
the announcement dated 31 March 2026, unless otherwise defined in this
announcement.

Enquiries:

 IXICO plc                                                            +44 (0) 20 3763 7499
  Grant Nash, Chief Financial Officer

 James Chandler, Chief Business Officer

 Cavendish Capital Markets Limited (Nominated advisor and broker)     +44 (0) 20 7220 0500
  Giles Balleny, Isaac Hooper, Andrea Callaghan (Corporate Finance)

 Nigel Birks (Healthcare Specialist Sales)

 Harriet Ward (Corporate Broking)

Michael F Johnson (Sales)

 

 About IXICO www.IXICO.com

 

IXICO is a global leader in neuroscience imaging and biomarker analytics,
using its proprietary AI-driven platform to help advance the treatment of
neurological disorders and reduce the uncertainties associated with drug
discovery, development and monitoring.  As a key part of the global
neurological disease research community, the Company has built a global
reputation and 20-year track record as an end-to-end Imaging Contract Research
Organisation (iCRO) working with leading pharma companies, innovative
biotechs, disease consortia and non-profit organisations. IXICO has supported
hundreds of neurological clinical trials, analysed hundreds of thousands scans
and built an expansive network of expert imaging centres around the world.

 

The IXI(TM) Platform is tailor-made for neurological disease, reliably
processing data from global trials, precisely measuring key imaging biomarkers
associated with the identification, progression and treatment of diseases such
as Alzheimer's, Huntington's and Parkinson's.  Image data is interrogated by
the Platform and IXICO's expert scientists translating complex data into
clinically meaningful while minimizing data variability and increasing
reproducibility.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.

  1   Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         1. Mark Warne

                                                                   2. Bram Goorden

                                                                   3. Katherine Rogers
 2    Reason for the notification
 a)   Position/status                                              1.   Chairman

                                                                   2.   Chief Executive Officer

                                                                   3.   Non-Executive Director
 b)   Initial notification /Amendment                              Initial notification
 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 a)   Name                                                         IXICO plc
 b)   LEI                                                          2138005M1F59O6HWSA97
 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 1 pence each

       Identification code

                                                                   GB00BFXR4C20
 b)   Nature of the transaction                                    1, 2 & 3: Subscription for New Ordinary Shares
 c)   Price(s) and volume(s)

  Price    Volume
                                                                   1 8 pence  125,000
                                                                   2 8 pence  937,500
                                                                   3 8 pence  62,500
 d)   Aggregated information                                        N/A - single transaction

       - Aggregated volume

       - Price
 e)   Date of the transaction                                      23 April 2026

 f)   Place of the transaction                                     Outside a trading venue

d)

 

Aggregated information

 - Aggregated volume

 - Price

 N/A - single transaction

e)

Date of the transaction

23 April 2026

 

f)

Place of the transaction

Outside a trading venue

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEFLFVLSTIFFIR



            Copyright 2019 Regulatory News Service, all rights reserved